Patents Represented by Attorney, Agent or Law Firm The Firm of Hueschen and Sage
  • Patent number: 6943184
    Abstract: A compound selected from those of formula (I): wherein: p represents an integer of from 0 to 6 inclusive, n represents an integer of from 0 to 6 inclusive, R1, and R2 represent a group selected from hydrogen, alkyl, aryl and arylalkyl, or R1+R2 form together with nitrogen carrying them saturated, monocyclic, or bicyclic system, X represents a group selected from oxygen, sulphur, a group —CH?CH—, methylene, a group of formula —HC?N—O— and a group of formula —O—CH2—CH?CH—, in which groups oxygen is linked to Y of the compounds of formula (I), Y represents a group selected from aryl, heteroaryl, arylalkyl, heteroarylalkyl, —C(O)-A, and —C(S)-A, A represents a group selected from alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, and NR3R4 wherein R3, and R4 represent a group selected from hydrogen, alkyl, aryl, and arylalkyl, or R3+R4 form together with nitrogen carrying them monocyclic, or bicyclic (C3-C10) system, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, a
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: September 13, 2005
    Assignee: Les Laboratories Servier
    Inventors: Solo Goldstein, Claude Guillonneau, Yves Charton, Brian Lockhart, Pierre Lestage
  • Patent number: 6930098
    Abstract: The present invention relates to the method of using polysulphated cyclodextrins or addition salts thereof for use in the treatment of arthrosis, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: August 16, 2005
    Assignee: Universiteit Gent
    Inventors: Eric Maximilien Veys, August Lodewijk Verbruggen
  • Patent number: 6919362
    Abstract: Compounds of formula (I): wherein: X represents an oxygen or a sulphur or CH2 or R1 and R2 represent a hydrogen atom, or a group as defined in the description, A represents an alkylene chain as described in the description, B is as defined in the description, R3 and R4 represent a hydrogen atom or a group as defined in the description, D represents an optionally substituted benzene, optionally substituted pyrazine, optionally substituted pyrimidine or optionally substituted pyridazine and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.
    Type: Grant
    Filed: February 1, 2001
    Date of Patent: July 19, 2005
    Assignee: Les Laboratoires Servier
    Inventors: Daniel Lesieur, Elodie Blanc-Delmas, Said Yous, Patrick Depreux, Gérald Guillaumet, Catherine Dacquet, Nigel Levens, Jean Albert Boutin, Caroline Bennejean, Pierre Renard
  • Patent number: 6913752
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: July 5, 2005
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
  • Patent number: 6908922
    Abstract: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions ins which endothelial dysfunction is known.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: June 21, 2005
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
  • Patent number: 6903103
    Abstract: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): wherein: X represents carbonyl, sulphonyl or sulphoxide, G1, G2 and G3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R1 represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, R2a and R2b, which are the same or different, are as defined in the description, R3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically a
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: June 7, 2005
    Assignee: Les Laboratories Servier
    Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
  • Patent number: 6894043
    Abstract: Compound selected from those of formula (I): wherein: X represents flourine, bromine, iodine or methyl, each of R1 and R2, which may be identical or different, represents hydrogen or alkyl, its isomers when they exist, and addition salts thereof with a pharmaceutically acceptable acid Medicinal products containing the same which are useful as AMPA modulators.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 17, 2005
    Assignee: Les Laboratoires Servier
    Inventors: Bernard Pirotte, Pascal De Tullio, Stéphane Boverie, Isabelle Kempen, Pierre Lestage
  • Patent number: 6878746
    Abstract: A compound selected from these of formula (I): wherein: R1 represents hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, heterocycloalkoxycarbonyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl or phosphono, R2 represents oxygen or sulphur, R3 represents hydrogen or alkyl, cycloalkyl or arylalkyl, X represents linear or branched (C1-C6)alkylene, R4 represents a group selected from amino optionally substituted by one or two groups, —N(R3)—X1—OR5 wherein R3, X1 and R5 are as defined in the description, —N(R3)—X1—NR6R7 wherein R3, X1, R6 and R7 are as defined in the description, hydroxy, alkoxy, aryloxy, —O—X1—OR5 wherein R5 and X1 are as defined in the description, and —O—X1—NR6R7 wherein R6, R7 and X1 are as defined in the description, its isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base, and medical products containing the same which are useful in the treatment of cancer.
    Type: Grant
    Filed: June 19, 2001
    Date of Patent: April 12, 2005
    Assignee: Les Laboratoires Servier
    Inventors: Claude Monneret, Emmanuel Bertounesque, Philippe Meresse, Ghanem Atassi, Alain Pierre, John Hickman, Bruno Pfeiffer, Pierre Renard
  • Patent number: 6875788
    Abstract: Compounds of formula (I): wherein: R1 represents an optionally substituted heteroaryl group, R2 represents an optionally substituted cycloalkyl group, R3 represents a hydrogen atom or an alkyl group, and R4 and R5 are as defined in the description, and Medicinal products containing the same are useful in the treatment of non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: April 5, 2005
    Assignee: Les Laboratoires Servier
    Inventors: Sylvain Rault, Marina Kopp, Jean-Charles Lancelot, Stéphane Lemaitre, Daniel-Henri Caignard, Jean-Guy Bizot-Espiard, Pierre Renard
  • Patent number: 6872851
    Abstract: The invention concerns compounds of formula (I): R—A—R? wherein: A is as defined in the description; R represent, a group (V), wherein R?a and R?a are as defined in the description, or R forms with A a cyclic structure as defined in the description; R? represents a (CH2)t—R2 group wherein q, t, and R2 are as defined in the description. The invention is useful for preparing medicines.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: March 29, 2005
    Assignee: Les Laboratories Servier
    Inventors: Daniel Lesieur, Frédérique Klupsch, Gérald Guillaumet, Marie-Claude Viaud, Michel Langlois, Caroline Bennejean, Pierre Renard, Philippe Delagrange
  • Patent number: 6846833
    Abstract: Compounds of formula (1): wherein: G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C, T1 represents —CH2—CH2—, —CH?CH— or ?CH—CH2—, and T2 is a bond, or T1 represents —CH2— or ?CH— and T2 is —CH2—, ?CH—, R5 represents —(CH2)m—COOR6, R6 and R6? represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl, A represents —CO—, —CH2—, ?CH— or —CH? and W represents —CH—, ?C— or —C?, or A represents —CO— or —CH2— and W represents N, X represents —CO—X1—, —CO—NR6—X1—, —NR6—CO—X1—, —O—X1—, —SO2—NR6—X1— or —S(O)n—X1—, Y represents —Y1—, —Y2—Y1— or —Y1—Y2—Y1—, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene, Z represents —Z1—, —Z10—NR6—, and —Z10—NR6—CO—, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroar
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: January 25, 2005
    Assignee: Les Laboratories Servier
    Inventors: Patrick Casara, Françoise Perron-Sierra, Ghanem Atassi, Gordon Tucker, Dominique Saint-Dizier
  • Patent number: 6844445
    Abstract: Compound of formula (I): wherein: R represents hydrogen or a group selected from alkenyl and optionally substituted alkyl, each of R1 to R8, which may be identical or different, represents hydrogen or a group selected from alkyl, alkenyl, hydroxy, alkoxy, alkenyloxy, arylalkyl, arylalkoxy, carboxy, acyloxy and arylcarbonyloxy, or one of R1 to R8 forms with an adjacent one R1 to R8 an alkylenedioxy group, its optical isomers when they exist, and addition salts thereof with a pharmaceutically acceptable acid or base, with the proviso that: when R does not represent hydrogen, then at least one of R1 to R8 represents hydroxy or acyloxy, and the compounds of formula (I) are other than indeno[1,2-b]indol-10(5H)-one and medicinal products containing the same which are useful for treatment of disorders of the melatoninergic system.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: January 18, 2005
    Assignee: Les Laboratoires Servier
    Inventors: Michel Wierzbicki, Marie-Françoise Boussard, Anne Rousseau, Jean Albert Boutin, Philippe Delagrange
  • Patent number: 6835843
    Abstract: The invention concerns a method for synthesis of perindopril of formula (I) and its pharmaceutically acceptable salts
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: December 28, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Pascal Langlois, Hugues Turbe
  • Patent number: 6828462
    Abstract: Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: December 7, 2004
    Assignee: Merz Pharma GmbH & Co. KGAA
    Inventors: Markus Henrich, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold
  • Patent number: 6818788
    Abstract: Stereoselective process for the industrial synthesis of compounds of formula (I): wherein R represents linear or branched (C1-C6)alkyl. Application in the synthesis of perindopril and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: November 16, 2004
    Assignee: Les Laboratoires Servier
    Inventor: Jean-Claude Souvie
  • Patent number: 6818657
    Abstract: The present invention relates to a ternary glucosyl complex which is a bioprecursor of at least one retinoic active ingredient for percutaneous application, having formula (I), wherein E represents a linear hydrocarbon spacer group that is branched or cyclized and has an aliphatic or aromatic content capable of containing one or several heteroatoms of oxygen and carrying one or several carbonyl groups; A represents a radical of a molecule of said retinoic active ingredient linked to the spacer group by a carboxylate function and n=1 or 2.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: November 16, 2004
    Assignee: Pierre Fabre Dermo-Cosmetique
    Inventors: Daniel Redoules, Roger Tarroux, Didier Fournier, Jean-Jacques Perie
  • Patent number: 6784183
    Abstract: Compounds of formula (I): and medicinal products containing the same which are useful as dual &agr;2/5-HT2c antagonists.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: August 31, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Gilbert Lavielle, Olivier Muller, Mark Millan, Anne Dekeyne, Mauricette Brocco
  • Patent number: 6780868
    Abstract: Compounds of formula (I): wherein: V represents a single bond or a linear or branched (C1-C6)alkylene chain, M represents a single bond or a linear or branched (C1-C6)alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i): X represents carbonyl, G1 represents a linear C3 alkylene chain optionally containing a double bond and/or being optionally substituted by a hydroxyl group, their isomers, their hydrates, their solvates, and additional salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: August 24, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
  • Patent number: 6774259
    Abstract: A stereoselective process for the industrial synthesis of compounds of formula (I): wherein R represents linear or branched (C1-C6)alkyl, and application in the synthesis of perindopril and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: August 10, 2004
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Claude Souvie, Alain Renaud
  • Patent number: 6761893
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: July 13, 2004
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger